{"nctId":"NCT01272232","briefTitle":"Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALEâ„¢ - Diabetes","startDateStruct":{"date":"2011-06-01","type":"ACTUAL"},"conditions":["Metabolism and Nutrition Disorder","Obesity"],"count":846,"armGroups":[{"label":"Lira 3.0 mg","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide"]},{"label":"Lira 1.8 mg","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide"]},{"label":"Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"liraglutide","otherNames":[]},{"name":"liraglutide","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent obtained\n* Subjects diagnosed with type 2 diabetes and treated with either diet and exercise alone, metformin, sulphonylurea, glitazone as single agent therapy or a combination of the previously mentioned compounds\n* HbA1c 7.0-10.0% (both inclusive)\n* Body Mass Index (BMI) at least 27.0 kg/m\\^2\n* Stable body weight\n* Preceding failed dietary effort\n\nExclusion Criteria:\n\n* Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors or insulin within the last 3 months\n* Known proliferative retinopathy or maculopathy\n* History of acute or chronic pancreatitis\n* Obesity induced by drug treatment\n* Use of approved weight lowering pharmacotherapy\n* Previous surgical treatment of obesity\n* History of major depressive disorder or suicide attempt\n* Uncontrolled hypertension (systolic blood pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)\n* Screening calcitonin of 50 ng/L or above\n* Familial or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)\n* Personal history of non-familial medullary thyroid carcinoma","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change (%) From Baseline in Body Weight (Fasting)","description":"Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.9","spread":"5.5"},{"groupId":"OG001","value":"-4.6","spread":"5.5"},{"groupId":"OG002","value":"-2.0","spread":"4.3"}]}]}]},{"type":"PRIMARY","title":"Proportion of Subjects Losing at Least 5% of Baseline Body Weight","description":"Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.9","spread":null},{"groupId":"OG001","value":"35.6","spread":null},{"groupId":"OG002","value":"13.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.1","spread":null},{"groupId":"OG001","value":"64.4","spread":null},{"groupId":"OG002","value":"86.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Subjects Losing More Than 10% of Baseline Body Weight","description":"Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4","spread":null},{"groupId":"OG001","value":"14.4","spread":null},{"groupId":"OG002","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"85.6","spread":null},{"groupId":"OG002","value":"95.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change (%-Points) From Baseline in HbA1c (Glycosylated Haemoglobin A1c)","description":"Change in HbA1c (%-points) was calculated as the difference between the HbA1c (%) at Week 0 and Week 56.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"0.9"},{"groupId":"OG001","value":"-1.1","spread":"1.0"},{"groupId":"OG002","value":"-0.3","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Reaching Target HbA1c Below 7%","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"27.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"72.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Reaching Target HbA1c Below or Equal to 6.5%","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":null},{"groupId":"OG001","value":"45.6","spread":null},{"groupId":"OG002","value":"15.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.5","spread":null},{"groupId":"OG001","value":"54.4","spread":null},{"groupId":"OG002","value":"85.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"6.5"},{"groupId":"OG001","value":"-4.8","spread":"5.6"},{"groupId":"OG002","value":"-2.7","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Change (%) From Baseline in Body Weight (Fasting)","description":"Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"5.0"},{"groupId":"OG001","value":"-3.6","spread":"5.7"},{"groupId":"OG002","value":"-2.7","spread":"5.8"}]}]}]},{"type":"SECONDARY","title":"Change (%) From Week 56 to 68 in Body Weight (Fasting)","description":"Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"2.9"},{"groupId":"OG001","value":"2.0","spread":"2.9"},{"groupId":"OG002","value":"-0.1","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","spread":"6.3"},{"groupId":"OG001","value":"-4.4","spread":"6.0"},{"groupId":"OG002","value":"-3.2","spread":"6.8"}]}]}]},{"type":"SECONDARY","title":"Change From Week 56 to 68 in Waist Circumference","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":"3.94"},{"groupId":"OG001","value":"1.02","spread":"3.55"},{"groupId":"OG002","value":"-0.22","spread":"3.23"}]}]}]},{"type":"SECONDARY","title":"Incidence of Hypoglycaemic Episodes","description":"Hypoglycaemic episodes were classified according to American Diabetes Association (ADA) definitions as well as to the Novo Nordisk definition of a minor hypoglycaemic event (blood glucose level below approximately 2.8 mmol/L \\[50 mg/dL\\] or plasma glucose level below 3.1 mmol/L \\[56 mg/dL\\]).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"142","spread":null},{"groupId":"OG002","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":37,"n":422},"commonTop":["Hypoglycaemia","Nausea","Diarrhoea","Nasopharyngitis","Headache"]}}}